Ionis Inhaled Antisense Drug Shows Potential In CF
Promising In COPD And Asthma Too
Executive Summary
The Phase I trial of IONIS-ENAC-2.5Rx for cystic fibrosis represents the first time an antisense medicine delivered directly to the lung has shown a significant reduction in ENaC messenger RNA levels.
You may also be interested in...
Vertex Suffers Setback In Its Search For Post-CF Blockbusters
Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.
Roche Returns To Cystic Fibrosis Fray With Enterprise Deal
While Vertex appears to have the cystic fibrosis market covered with its CFTR modulators, Enterprise has been exploring another channel, TMEM16A, in the hope of developing compounds that could possibly be used by everybody with the lethal genetic disease.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.